QSIAW — Quantum-Si incorporated

Quantum-Si (QSIAW) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $451,000, impacted by capital sales headwinds.
• Full Year 2025 Revenue: $2.4 million, with a gross profit of $1.2 million (47% gross margin).
• Q4 Gross Profit: $122,000 (27% gross margin), affected by a higher proportion of consumable revenue.
• Operating Expenses: Q4 GAAP total operating expenses were $21.2 million, down from $31.3 million in Q4 2024. Full-year GAAP operating expenses were $117.3 million, up from $110.2 million in 2024.
• Cash Position: As of December 31, 2025, the company had $215.8 million in cash and investments.

2. Strategic Updates and Business Highlights

• Corporate Priorities: Focus on accelerating commercial adoption, delivering innovation, and preserving financial strength.
• Consumable Revenue Growth: The company secured 17 new customers through an expanded instrument acquisition program, which allows labs to utilize instruments without upfront capital costs.
• Publication Pipeline: Five manuscripts submitted in 2025, with three published in early 2026, showcasing diverse applications of the technology.
• Proteus Development: The company is preparing for the launch of the Proteus system at the end of 2026, with a list price set at $425,000. Initial feedback indicates strong interest from potential customers.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be approximately $1 million, primarily from consumables and services, with very limited capital sales.
• Operating Expenses: Anticipated adjusted operating expenses of $98 million or less, with total cash usage projected at $93 million or less.
• Long-term Focus: The company is prioritizing long-term platform adoption over immediate revenue maximization, particularly as it prepares for the Proteus launch.

4. Bad News, Challenges, or Points of Concern

• Capital Sales Headwinds: The company has faced challenges due to delays in NIH funding and uncertainty around capital budgets, impacting sales of the Platinum Pro instrument.
• Limited Capital Sales: Expectations for modest new placements of capital equipment in 2026, with a focus on consumables instead.
• Operational Risks: Potential delays in the development and launch of Proteus due to hardware integration and manufacturing challenges.
• Gross Margin Pressure: Anticipated lower gross margins in 2026 due to the shift towards consumable revenue, which typically has lower margins compared to capital equipment sales.

5. Notable Q&A Insights

• Consumable Trends: Management indicated a more than 25% increase in consumable kits expected in 2026, with a focus on customer engagement and utilization.
• Customer Feedback: Customers are hesitant to invest in Platinum Pro due to the upcoming Proteus launch, leading to a strategy focused on placements and consumables.
• Market Preparation: The decision to announce the Proteus price early was driven by customer demand for budgeting purposes, not due to secured preorders.
• Sales Strategy: The company is evaluating the potential for leasing options for Proteus but is initially focusing on direct capital sales.
• Long-term Growth Drivers: The importance of achieving 20 amino acid detection capabilities is acknowledged, but not seen as critical for initial customer adoption of Proteus.

Overall, Quantum-Si is navigating a transition year with a strategic focus on preparing for the Proteus launch while managing current revenue challenges and operational risks.